Savar Sinha

As seen in: medRxiv

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Savar

Contact Savar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in AR-altered lethal prostate cancer

Dec 01, 2023 |

By Pradeep Chauhan, Irfan Alahi, Savar Sinha, Alexander L. Shiang

| medRxiv

P.S.C., I.A., and A.A.C. have patent filings related to cancer biomarkers. F.Q. has stock options in Centene, Gilead, and Horizon Therapeutics. O.S. served as a consultant to JNJ and Pfizer and grant support to institution for JNJ.

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with Savar

Contact Savar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

Savar Sinha

Get in touch with Savar

Actions

Is this you?

Articles

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in AR-altered lethal prostate cancer

Actions

Is this you?

Get in touch with Savar